Chronic Myeloid Leukemia Excellence Forum

Chronic Myeloid Leukemia

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Interview

Data Support Using Bosutinib Therapy for Treatment of Chronic-Phase CML

07/21/2020

Sonia Amin Thomas, PharmD, BCOP, discusses data regarding the safety and efficacy of bosutinib therapy for patients with chronic-phase CML.

Sonia Amin Thomas, PharmD, BCOP,...

07/21/2020

Oncology

Podcasts

Interim Analysis Suggests Correlation Between Ponatinib Dosing and Efficacy in CML

06/11/2020

Jorge Cortes, MD, discusses results from an interim analysis of the OPTIC trial, evaluating the association between ponatinib exposure, efficacy, and safety with response-based dose reduction in CML.

Jorge Cortes, MD, discusses...

06/11/2020

Oncology

Interview

Asciminib Shows Activity in Pretreated Patients With CML

04/27/2020

Michael Mauro, MD, spoke about the findings of a phase 1 trial evaluating the use of asciminib, an ABL1 kinase inhibitor, in heavily pretreated CML.

Michael Mauro, MD, spoke about...

04/27/2020

Oncology

Podcasts

TKI Discontinuation in Patients With CML

04/07/2020

Ehab Atallah, MD, discusses the do’s and don’ts of TKI treatment discontinuation in patients with CML.

Ehab Atallah, MD, discusses the...

04/07/2020

Oncology

Podcasts

Post-Transplant TKI Salvage Therapy Provides Significant Survival Benefit Following Relapse in CML

03/23/2020

Sarah Schmidt, PharmD, BCPS, BCOP, discusses results from a retrospective analysis evaluating the role of donor lymphocyte infusion in patients with CML who relapse post-transplant in the TKI era.

Sarah Schmidt, PharmD, BCPS,...

03/23/2020

Oncology

Podcasts

Novel ABL1 Kinase Inhibitor Active in Heavily Pretreated CML

02/01/2020

Michael Mauro, MD, discusses results from a phase 1 trial which evaluated asciminib, an ABL1 kinase inhibitor, in patients with heavily pretreated CML.

Michael Mauro, MD, discusses...

02/01/2020

Oncology

Resource

Chronic Myelogenous Leukemia Treatment (PDQ®)–Health Professional Version

01/29/2020

Chronic myelogenous leukemia treatments include tyrosine kinase inhibitors, high-dose therapy with allogeneic transplantation, and other medications. Get detailed information about chronic myelogenous leukemia (CML) treatment options in this...

Chronic myelogenous leukemia...

01/29/2020

Oncology

Podcasts

Gabriella Hobbs, MD, Discusses Treatment Options for Patients With CML

11/08/2018

In this 3-part podcast series, Gabriela Hobbs, MD, answers a series of questions about how she treats patients with CML.

In this 3-part podcast series,...

11/08/2018

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology